LakeShore Biopharma Co., Ltd (LSBCF)
OTC PINK OTC PINK Primary Summary
LakeShore Biopharma Co., Ltd (LSBCF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has LakeShore Biopharma Co., Ltd ever had a stock split?
LakeShore Biopharma Co., Ltd Profile
| Biotechnology Industry | Healthcare Sector | Wang Xu CEO | OTC PINK Exchange | G9845F208 CUSIP |
| CN Country | 758 Employees | - Last Dividend | - Last Split | 16 Mar 2023 IPO Date |
Overview
LakeShore Biopharma Co., Ltd is a forward-looking biopharmaceutical entity committed to the research, development, production, and sale of vaccines and therapeutic biologics targeting infectious diseases and cancer. Born from its predecessor, YS Biopharma Co., Ltd., LakeShore Biopharma transitioned its name in May 2024, a move reflecting its evolution and expanded vision. Established in 2002 and headquartered in Beijing, China, the company exercises a global footprint through its operations in China, the United States, Singapore, the United Arab Emirates, and the Philippines. At its core, LakeShore Biopharma is pioneering through its proprietary PIKA immunomodulating technology platform, a testament to its innovative direction in the biopharmaceutical industry.
Products and Services
- PIKA Rabies Vaccine
- PIKA Recombinant COVID-19 Vaccine
- PIKA YS-ON-001
A groundbreaking vaccine leveraging the PIKA technology platform, this product represents a significant advancement in the prevention of rabies, a critical public health issue worldwide. The PIKA rabies vaccine is designed to offer enhanced immunogenicity and safety, targeting a wide demographic with its innovative approach to rabies vaccination.
In response to the global pandemic, LakeShore Biopharma developed the PIKA recombinant COVID-19 vaccine, utilizing its novel PIKA platform to provide a potentially more efficacious and safer alternative to existing COVID-19 vaccines. This product underscores the company's agility and commitment to addressing emergent global health crises through cutting-edge biotechnological advancements.
Expanding its portfolio into the realm of cancer therapy, LakeShore Biopharma's PIKA YS-ON-001 is a testament to the company's innovative application of its PIKA platform beyond infectious diseases. This therapeutic biologic is aimed at harnessing the body's immune response to target and combat various forms of cancer, illustrating LakeShore Biopharma's ambitious endeavor into oncology.
